TLDR:
- ORI Capital has closed its second life sciences fund, ORI Fund II, at $260 million.
- The fund will focus on investing in early-stage biotech companies.
ORI Capital has successfully closed its sophomore life sciences fund, ORI Fund II, at $260 million. The fund will be targeted towards investing in early-stage biotech companies. This fund is a testament to the continued interest and growth in the life sciences sector, particularly in the biotech industry.
ORI Capital’s decision to focus on early-stage biotech companies highlights the potential for significant returns in this sector. By investing in companies at their early stages, ORI Capital has the opportunity to influence the growth and success of these biotech startups, while also benefiting from potential future successes.
Overall, ORI Capital’s successful fundraising for its second life sciences fund demonstrates investor confidence in the biotech industry and the potential for significant returns in early-stage investments.
